Clinical Trials - The Bloodline with Blood Cancer United Podcast

Curious about what’s new in the world of myelodysplastic syndromes (MDS)? We’re bringing you the latest insights straight from one of the field’s leading experts.

In this episode, we speak with Dr. Mikkael Sekeres, of the Sylvester Comprehensive Cancer Center at University of Miami Health. Recorded onsite at the 2025 ASH (American Society of Hematology) Annual Meeting and Exposition, this conversation explores what MDS is, how it’s treated today, and what researchers are learning about managing side effects.

Dr. Sekeres also walks us through the most notable MDS updates presented at ASH, highlighting promising therapies and clinical trial data that may help shape future care. Whether you’re newly learning about MDS or following ongoing research, this episode offers an accessible look at where things stand and what’s on the horizon.

*This is not an official program of the ASH annual meeting

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Geron Corporation and Taiho Oncology, Inc.

The post The Bloodline Live! Myelodysplastic Syndromes (MDS) Updates in Research first appeared on The Bloodline with Blood Cancer United Podcast.

In this episode, we are joined by Dr. Abdulraheem Yacoub of The University of Kansas Cancer Center to discuss myeloproliferative neoplasms (MPN), a group of rare blood cancers that affect how blood cells are produced. We explore what MPNs are, the most common types, and the signs and symptoms that lead to diagnosis. We also answer real questions from members of our MPN online chat community, covering topics like life expectancy, genetic mutations, and managing side effects. Finally, we discuss current treatment options, emerging therapies, and share a message of hope for patients and their loved ones.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by PharmaEssentia USA Corporation.

The post After Diagnosis: Finding Hope with Myeloproliferative Neoplasms first appeared on The Bloodline with Blood Cancer United Podcast.

Curious about CAR T-cell therapy? We went straight to the source for answers.

In this episode, the LLS Patient Education team visited The University of Miami Sylvester Cancer Center to meet with Dr. Trent Wang. He answered some of the most frequently asked questions from our patients and caregivers about this innovative cancer treatment – from who’s eligible and what to expect, to side effects, caregiver roles, and exciting future developments.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Bristol Myers Squibb; Johnson & Johnson & Legend Biotech; and Kite, a Gilead Company.

The post CAR T-cell Therapy: Your Questions Answered first appeared on The Bloodline with Blood Cancer United Podcast.

Acute myeloid leukemia (AML) is one of the most aggressive blood cancers—but science is making real progress. In this episode, Dr. Eytan Stein of Memorial Sloan Kettering breaks down what makes AML so challenging to treat, how it’s classified, and the latest therapies changing the outlook for patients. From combination therapies and menin inhibitors to future research on CAR T-cell therapy and bispecifics, this is a hopeful, expert-led look at the future of AML treatment.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Abbvie Inc.; Astellas Pharma US Inc.; Genentech, A Member of the Roche Group; and Kura Oncology, Inc.

The post Understanding AML: The Challenges, The Progress, The Hope first appeared on The Bloodline with Blood Cancer United Podcast.

In this episode, we sit down with Dr. Cesar Rodriguez of Mount Sinai Hospital in New York, NY to discuss the evolving landscape of myeloma treatment. Groundbreaking innovations are bringing new hope to patients and caregivers. Dr. Rodriguez breaks down the latest advancements in immunotherapy, including CAR T-cell therapy and bispecific antibodies. Hear how researchers and physicians are working to make myeloma into a manageable, long-term disease, while ultimately searching for a cure.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Abbvie Inc.; Genentech, A Member of the Roche Group; and Johnson & Johnson.

The post Hope in Myeloma: The Road to Long-Term Survival first appeared on The Bloodline with Blood Cancer United Podcast.

A Cutaneous T-cell Lymphoma (CTCL) diagnosis can raise many questions, from understanding symptoms to exploring treatment options.  In this episode, we talk to Dr. Francine Foss of Yale University to break down what CTCL is, how to manage side effects, and the latest advancements in treatment—including promising immunotherapies like CAR T-cell therapy and bispecific antibodies.  We also discuss the critical role of clinical trials in shaping the future of CTCL care.  

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Kyowa Kirin, Inc.

The post Cutaneous T-Cell Lymphoma (CTCL): From Diagnosis to Innovation first appeared on The Bloodline with Blood Cancer United Podcast.

In this episode, we sit down with Dr. Bilal Abid from University of Texas Health Science Center in Houston to discuss how healthcare disparities have an effect on cancer care — especially when it comes to cutting-edge treatments such as stem cell transplantations and CAR T-cell therapy. We discuss how race, socioeconomic status, education, and geographic location can determine a patient’s access to cancer care. With travel, insurance, and systemic barriers in the mix, we explore what patients can do to navigate these challenges, and how treatment centers and policymakers are contributing to ensure equitable access to care for all patients.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Genentech, A Member of the Roche Group.

The post Impact of Disparity: Navigating Treatment Equality in Cancer Care first appeared on The Bloodline with Blood Cancer United Podcast.

A stem cell transplant for blood cancer is just the beginning – what may come next for the patient can be a complex journey. In this episode, Dr. Alison Loren of the University of Pennsylvania discusses graft-vs-host disease (GVHD), a possible complication of transplantation – exploring the latest advancements in treatment and how patients and caregivers can navigate the challenges ahead.

Mentioned on this episode: 

Additional LLS Support Resources: 

The post Beyond the Transplant: Navigating Graft-vs-Host Disease (GVHD) first appeared on The Bloodline with Blood Cancer United Podcast.

Research continues to accelerate for myelodysplastic syndromes (MDS), giving hope to patients and their loved ones. In this episode, Dr. William Shomali of Stanford University dives into cutting-edge treatments for both low and high-risk MDS. Learn about the innovative therapies that are enhancing quality of life and explore the promising strides towards curative treatments. Don’t miss this inspiring conversation filled with valuable insights and hope for a brighter future.  

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by Geron Corporation and Taiho Oncology, Inc.

The post There’s Always Hope: Myelodysplastic Syndromes (MDS) first appeared on The Bloodline with Blood Cancer United Podcast.

Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma. Tune in as we chat with Dr. Yasmin Karimi from the University of Michigan about the latest breakthroughs in treatment, including combination therapies, CAR T-cell therapy and bispecific antibodies. Discover how these innovations are offering new hope and pathways to cures for patients.

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by Genmab US, Inc.

The post Emerging Therapies and Hope: Diffuse Large B-cell Lymphoma first appeared on The Bloodline with Blood Cancer United Podcast.